SRC and non-small cell lung carcinoma: The percentage of Src phosphorylation in NSCLC is significant and preclinical data suggest that it may be responsible for the decreased response to pemetrexed; thus, examining Src inhibition by an agent such as Bosutinib may be a reasonable option.